Skip to main content

Table 1 Characteristics of all 87 included patients

From: Relationship between acid–base status and inflammation in the critically ill

Demographic features

Value

Age, years

52 (35 to 60)

Male, number of patients (%)

46 (53%)

Simplified acute physiology score 3

52 (41 to 67)

Sequential organ failure assessment score at admission

5 (2 to 9)

Laboratory data at admission

 

Hemoglobin, g/dL

11 (2.32)

Hematocrit (%)

33.4 (6.8)

Leucocytes, cells/mm3

11,070 (7,400 to 16,000)

Platelets, units/mm3

174 (130 to 260)

Na, mEq/L

140 (9.2)

K, mEq/L

4.1 (0.9)

Cl, mEq/L

106 (9.4)

P, mg/dL

2.24 (0.99)

Creatinine, mg/dL

1.24 (0.8 to 2.8)

pH

7.39 (7.33 to 7.41)

pCO2, mmHg

38.72 (10.8)

HCO3-, mEq/L

21.83 (5.0)

SBE, mEq/L

-2.9 (5.5)

SIG, mEq/L

8.92 (5.13)

SIDa, mEq/L

40.7 (4.89)

Lactate, mEq/L

1.55 (1.11 to 2.22)

Albumin, g/dL

2.91 (0.73)

Specific reasons for admission, number of patients (%)

 

Sepsis

27 (31%)

Surgery

3 (3%)

Organ dysfunction and need for support, number of patients (%)

 

Shock

25 (28%)

Norepinephrine dose <0.3 mcg/kg/min

8 (9%)

Norepinephrine dose ≥0.3 mcg/kg/min

18 (20%)

Steroid use for shock

18 (20%)

Use of mechanical ventilation

19 (22%)

PO2/FiO2 ratio <100

1 (1%)

Acute kidney injury

27 (31%)

Need for renal replacement therapy

25 (29%)

Continuous method

14 (16%)

Outcomes, number of patients (%)

 

ICU mortality

20 (23%)

Hospital mortality

26 (30%)

Cytokine levels, pg/mL

 

IL1β

2.1 (1.2 to 4.1)

IL1RA

25.4 (12 to 59.7)

IL2

7.5 (4.9 to 12.8)

IL4

7.18 (2.41 to 18.76)

IL6

45.76 (11.2 to 110)

IL7

13.3 (7.0 to 20.9)

IL8

36.3 (19.3 to 81.8)

IL9

2.0 (0.2 to 3.7)

IL10

17.7 (7.4 to 57.9)

IL17

3.5 (1.8 to 8.1)

TNFα

25.7 (12.5 to 45.0)

IFNα

66.3 (52.5 to 93.2)

IFNγ

9.4 (5.4 to 16.8)

VEGF

161 (104 to 311)

CXCL1

1275 (901 to 2,338)

MCP1

401 (226.5 to 1,450.0)

  1. Data are shown as mean (SD) or median (IQ) unless stated otherwise. PO2/FiO2, partial pressure of dissolved oxygen/inspired oxygen fraction; VEGF, vascular endothelial growth factor; CXCL, chemokine CXC motif ligand; MCP, monocyte chemoattractant protein.